3,162 Shares in Verona Pharma PLC American Depositary Share $VRNA Purchased by R Squared Ltd

R Squared Ltd acquired a new position in Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 3,162 shares of the company’s stock, valued at approximately $299,000.

Several other institutional investors also recently modified their holdings of VRNA. Adage Capital Partners GP L.L.C. grew its position in shares of Verona Pharma PLC American Depositary Share by 381.9% during the 1st quarter. Adage Capital Partners GP L.L.C. now owns 1,631,000 shares of the company’s stock worth $103,552,000 after buying an additional 1,292,575 shares during the period. Lord Abbett & CO. LLC acquired a new position in shares of Verona Pharma PLC American Depositary Share during the 1st quarter worth about $58,716,000. Goldman Sachs Group Inc. grew its position in shares of Verona Pharma PLC American Depositary Share by 274.5% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,041,408 shares of the company’s stock worth $66,119,000 after buying an additional 763,353 shares during the period. Allspring Global Investments Holdings LLC acquired a new position in shares of Verona Pharma PLC American Depositary Share during the 1st quarter worth about $33,150,000. Finally, TimesSquare Capital Management LLC acquired a new position in shares of Verona Pharma PLC American Depositary Share during the 1st quarter worth about $31,526,000. 85.88% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Verona Pharma PLC American Depositary Share

In other Verona Pharma PLC American Depositary Share news, Director David R. Ebsworth sold 1,904 shares of the business’s stock in a transaction that occurred on Friday, August 1st. The stock was sold at an average price of $13.14, for a total value of $25,018.56. Following the sale, the director owned 880,499 shares in the company, valued at approximately $11,569,756.86. The trade was a 0.22% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO David Zaccardelli sold 208,912 shares of the business’s stock in a transaction that occurred on Friday, August 1st. The shares were sold at an average price of $13.14, for a total value of $2,745,103.68. Following the completion of the sale, the chief executive officer owned 13,376,144 shares in the company, valued at $175,762,532.16. The trade was a 1.54% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 540,584 shares of company stock worth $7,103,274. Corporate insiders own 4.80% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the company. Roth Capital lowered Verona Pharma PLC American Depositary Share from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 10th. HC Wainwright reiterated a “neutral” rating and issued a $107.00 price objective (up from $90.00) on shares of Verona Pharma PLC American Depositary Share in a research report on Monday, July 14th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $100.00 price objective on shares of Verona Pharma PLC American Depositary Share in a research report on Wednesday, October 8th. TD Cowen lowered Verona Pharma PLC American Depositary Share from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, July 9th. Finally, Wells Fargo & Company lowered Verona Pharma PLC American Depositary Share from a “strong-buy” rating to a “hold” rating and decreased their price objective for the company from $138.00 to $107.00 in a research report on Thursday, July 10th. Two investment analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $109.00.

Verona Pharma PLC American Depositary Share Stock Performance

NASDAQ VRNA opened at $106.91 on Friday. The stock has a market capitalization of $9.21 billion, a price-to-earnings ratio of -107.99 and a beta of 0.05. The stock’s 50 day moving average price is $106.41 and its two-hundred day moving average price is $92.62. The company has a debt-to-equity ratio of 0.87, a quick ratio of 10.54 and a current ratio of 10.71. Verona Pharma PLC American Depositary Share has a 52 week low of $31.09 and a 52 week high of $106.93.

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) last released its earnings results on Wednesday, August 6th. The company reported $0.13 EPS for the quarter, beating the consensus estimate of ($0.01) by $0.14. The firm had revenue of $103.14 million for the quarter, compared to analysts’ expectations of $90.41 million. Verona Pharma PLC American Depositary Share had a negative return on equity of 21.12% and a negative net margin of 36.62%. As a group, analysts anticipate that Verona Pharma PLC American Depositary Share will post -1.95 earnings per share for the current fiscal year.

Verona Pharma PLC American Depositary Share Company Profile

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.